Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-05-16
2006-05-16
Priebe, Scott D. (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S091400, C435S455000, C435S456000, C424S093200
Reexamination Certificate
active
07045348
ABSTRACT:
The present invention provides a recombinant adenovirus vector targeted by zipper peptides. The vector contains a fiber protein modified by insertion of a first zipper peptide that can crosslink to a fusion protein comprising a second zipper peptide and a targeting ligand. Binding of the first zipper peptide to the second zipper peptide forms a targeted vector: ligand complex, thereby targeting the adenovirus vector to a cell that expresses a cell surface molecule that binds to said targeting ligand.
REFERENCES:
patent: 6210946 (2001-04-01), Curiel et al.
patent: 6284742 (2001-09-01), Curiel et al.
Bodey et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Res. 20: 2665-2676, 2000.
Radoja et al., “Cancer-induced defective cytotoxic T lymphocite effector function: another mechanism how antigenic tumors escape immune-mediated killing,” Mol Med 6(6): 465-479, 2000.
Basak et al., “Modifying adenoviral vectors for use as gene-based cancer vaccines,” Viral Immunol. 17 (2): 2182-196, Jun. 2004.
Arndt et al.; A Heterodimeric Coiled-coil Peptide Pair Selected in Vivo from a Designed Library-versus-Library Ensemble; J. Mol. Biol. (2000) 295, 627-639.
Asada-Mikami et al.; Efficient Gene Transduction by RGD-fiber Modified Recombinant Adenovirus into Dendritic Cells; Jpn. J. Cancer Res. 92, 321-327, Mar. 2001.
Banchereau & Steinman; Dendritic cells and the control of immunity: NATURE, vol. 392, Mar. 19, 1988: pp. 245-252.
Belousova et al., Generation of recombinant adenoviral vectors containing fiber proteins with extended HI-loops; Molecular Therapy vol. 3, No. 5, May 2001, S168.
Belousova et al., Genetically Targeted Adenovirus Vector Directed to CD40-Expressing Cells; Journal of Virology; Nov. 2003; vol. 77, No. 21; pp. 11367-11377.
Bewig & Schmidt; Accelerated Titering of Adenoviruses; Biotechniques, vol. 28, No. 5 (2000).
Bocchia et al., Antitumor vaccination: where we stand; Haematologica 2000; 85:1172-1206.
Boon et al., Tumor Antigens Recognized By T Lymphocytes. Thierry Boon, Jean-Charles Cerottini, Benoit Van den Eynde, Pierre van der Bruggen, Aline Van Pel: Annu. Rev. Immunol. 1994: 12-337-65.
Brand et al.; Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors: Cancer Gene Therapy, vol. 4, No. 1, 1997, pp. 9-16.
Brossart et al.; Virus-Mediated Delivery of Antigens Epilopes into Dendritic Cells as a Means to Induce CTL; The Journal of Immunology, 1997, 158:3270-3276.
Correale et al., In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen; Journal of the National Cancer Institute; vol. 89, No. 4, Feb. 19, 1997.
Coulie et al., Antigens recognized by T-lymphocytes on human tumours; Biochemical Society Transactions, vol. 25, 1997.
Dietz and Vuk-Pavlovic High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells: Blood. vol. 91. No. 2 (Jan. 15, 1998): pp. 392-398.
Dmitriev et al.; An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism: Journal of Virology, Dec. 1988, pp. 9706-9713.
Dmitriev et al.; Ectodomain of Coxsackievirus and Adenorvirus Receptor Genetically Fused to Epidermal Growth Factor Mediales Adenovirus Targeting to Epidermal Growth Factor Receptor-Positive Cells: Journal of Virology, Aug. 2000, pp. 6875-6884.
Douglas et al., A system for the propagation of adenoviral vectors with genetically modified receptor specificities: Nature Biotechnology, May 1999, vol. 17, pp. 470-474.
Fong and Engleman: Dendritic Cells in Cancer Immunotherapy: Annu. Rev. Immunol. 2000, 18:245-273.
Freimuth; A Human Cell Line Selected for Resistance to Adenovirus Infection Has Reduced Levels of the Virus Receptor; Journal of Virology. Jun. 1996, pp. 4081-4085.
Gong et al.; Reversal of tolerance to human MUCI antigen in MUCI antigen in MUCI transgenic mice immunized with fusions of dendritic and carcinoma cells; Proc. Natl. Acad. Sci. USA. vol. 95, pp. 6279-6283, May 1998.
Hodges; De novo design of o-helical proteins: basic research to medical applications: Biochem. Cell Biol. 74: 133-154 (1996).
Hong & Engler; Domains Required for Assembly of Adenovirus Type 2 Fiber Trimers; Journal of Virology, Oct. 1996, p. 7071-7078.
Hsu et al; Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dentrilic cells; Nature Medicine, vol. 2, No. 1, Jan. 1996, pp. 52-58.
Hurst; Transcription Factors I: bZIP proteins: Protein Profile, vol. 2, Issue 2, pp. 105-168.
Kaplan et al.; Induction of Antitumor Immunity with Dendritic Cells Transduced wtih Adenovirus Vector-Encoding Endogenous Tumor-Associated Antigens; The Journal of Immunology, Apr. 30, 1999, pp. 699-707.
Katz et al.; Green Fluorescent Protein Labeling of Cytoskeletal Structures—Novel Targeting Approach Based on Leucine Zippers; BioTechniques, vol. 25, No. 2 (1998), pp. 298-303.
Krasnykh et al.; Generation of Recombinant Adenovirus Vectors with Modified Fibers for Altering Viral Tropism: Journal of Virology, Oct. 1996, pp. 6839-6846.
Krasnykh et al.; Characterization of an Adenovirus Vector Containing a Heterologous Peptide Epitope in the HI Loop of the Fiber Knob; Journal of Virology, Mar. 1998, pp. 1844-1852.
Krasnykh et al.; Genetic Targeting of an Adenovirus Vector via Replacement of the Fiber Protein with the Phage T4 Fibritin; Journal of Virology, May 2001, pp. 4176-4183.
Kugler et al.; Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids; Nature Medicine, vol. 6, No. 3, Mar. 2000, pp. 332-336.
Kwak et al.; Induction of Immune Responses in Patients with B-Cell Lymphoma Against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors; The New England Journal of Medicine, vol. 327, No. 17, pp. 1209-1215.
Lee et al.; Phenotype, Function, and In Vivo Migration and Survival of Allogeneic Dendrilic Cell Progenitors Genetically Engineered to Express TGF-β; Transplantation, vol. 66, pp. 1810-1817, No. 12, Dec. 27, 1998.
Lozier et al.; Adenovirus-Mediated Expression of Human Coagulation Factor IX in the Rhesus Macaque Is Associated With Dose-Limiting Toxicity; Blood, vol. 94, No. 12, Dec. 15, 1999, pp. 3968-3975.
Mathias et al.; Interactions of Soluble Recombinant Integrin avβ5 with Human Adenoviruses; Journal of Virology, Nov. 17, 1998, pp. 8669-8675.
Mayordomo et al.; Bone Marrow-Derived Dendritic Cells Serve as Potent Adjuvants for Peptide-Based Antitumor Vaccines; Stem Cells 1997; 15:94-103.
Michael et al.; Addition of a short peptide ligand to the adenovirus fiber protein; Gene Therapy (1995) 2. 660-668.
Mittereder et al.; Evaluation of the Concentration and Bioactivity of Adenovirus Vectors for Gene Therapy; Journal of Virology, Nov. 1996, pp. 7498-7509.
Moll et al.; Designed heterodimerizing leucine zippers with a range of pls and stabilities up to 10.13M; Protein Science (2001), 10:649-655.
Morris et al.; Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154); The Journal of Biological Chemistry, vol. 274, No. 1, Issue of Jan. 1, pp. 418-423, 1999.
Murphy et al.; Phase II Prostate Cancer Vaccine Trial: Report of a Study Involving 37 Patients with Disease Recurrence Following Primary Treatment; The Prostate 39:54-59 (1999).
Nestle et al.; Vaccination of meanoma patients with peptide- or tumor lysate-pulsed dendritic cells; Nature Medicine, vol. 4, No. 3, Mar. 1998, pp. 328-332.
Okada et al.; Efficient Gene Delivery into dendritic Cells by Fiber-Mutant Adenovirus Vectors: Biochemical and Biophysical Research Communications 282, 173-179 (2001).
O'Neal et al.; Toxicological Comparison of E2o-Deleted and First-Generation Adenoviral Vectors Expressing o1- Antitrypsin after Systemic Delivery; Human Gene Therapy 9:1587-1598 (Jul. 20, 1998).
O'Neal et al.; Toxicity Associated with Repeated Administration of First-Generation Adenovirus Vectors Does Not Occur with a Helper-Dependent Vector; Molecular Me
Korokhov Nikolay
Mikheeva Galina
Frommer & Lawrence & Haug LLP
Kowalski Thomas J.
Lu Deborah L.
Priebe Scott D.
Vectorlogics, Inc.
LandOfFree
Adenoviral vector incorporating zipper peptide-modified... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenoviral vector incorporating zipper peptide-modified..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenoviral vector incorporating zipper peptide-modified... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3548122